Eisai Co Ltd
TSE:4523

Watchlist Manager
Eisai Co Ltd Logo
Eisai Co Ltd
TSE:4523
Watchlist
Price: 4 277 JPY 0.45% Market Closed
Market Cap: 1.2T JPY
Have any thoughts about
Eisai Co Ltd?
Write Note

Eisai Co Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Eisai Co Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Eisai Co Ltd
TSE:4523
Accounts Receivables
ÂĄ205.4B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
2%
Takeda Pharmaceutical Co Ltd
TSE:4502
Accounts Receivables
ÂĄ700.5B
CAGR 3-Years
-6%
CAGR 5-Years
-2%
CAGR 10-Years
4%
Daiichi Sankyo Co Ltd
TSE:4568
Accounts Receivables
ÂĄ531.8B
CAGR 3-Years
24%
CAGR 5-Years
9%
CAGR 10-Years
7%
Otsuka Holdings Co Ltd
TSE:4578
Accounts Receivables
ÂĄ470.4B
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
4%
Chugai Pharmaceutical Co Ltd
TSE:4519
Accounts Receivables
ÂĄ239.7B
CAGR 3-Years
-6%
CAGR 5-Years
4%
CAGR 10-Years
6%
Astellas Pharma Inc
TSE:4503
Accounts Receivables
ÂĄ558.3B
CAGR 3-Years
16%
CAGR 5-Years
11%
CAGR 10-Years
5%
No Stocks Found

Eisai Co Ltd
Glance View

Market Cap
1.2T JPY
Industry
Pharmaceuticals

Eisai Co., Ltd., established in 1941, has emerged as a formidable player in the global pharmaceutical landscape, forging its reputation through a steadfast commitment to "human health care" (hhc). Rooted in Tokyo, the company orbits around the development of innovative treatments targeting neurology and oncology, positioning itself as a beacon of hope for patients worldwide. Eisai's journey is characterized by a persistent focus on medicinal breakthroughs in areas such as Alzheimer’s disease, liver cancer, and epilepsy—disease states that critically affect the quality of life but often have limited treatment options. Through its rigorous research and development efforts, the company crafts both small molecule drugs and biologics, distinguishing itself with flagship products like Aricept for Alzheimer's and Lenvima for cancer, both of which have cemented its reputation in the medical community and are vital streams of revenue. Eisai's business framework is intricately woven into a global tapestry of partnerships and collaborations, which amplifies its market reach and bolsters its financial performance. By strategically aligning with global pharmaceutical giants and leveraging robust patent portfolios, Eisai extends its innovative therapies to numerous markets. This strategic network allows it to not only enhance drug distribution and sales but also to engage in co-development, introducing shared stewardship in groundbreaking research. The company's financial structure is further reinforced through a diversified portfolio, inclusive of both branded prescription drugs and over-the-counter products, thus facilitating consistent cash flow and enabling ongoing investments in research. These deliberate steps underscore Eisai's pursuit of longevity in a fiercely competitive industry, ensuring it remains well-poised to continually adapt and thrive amidst evolving healthcare challenges.

Intrinsic Value
7 097.77 JPY
Undervaluation 40%
Intrinsic Value
Price

See Also

What is Eisai Co Ltd's Accounts Receivables?
Accounts Receivables
205.4B JPY

Based on the financial report for Sep 30, 2024, Eisai Co Ltd's Accounts Receivables amounts to 205.4B JPY.

What is Eisai Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
2%

Over the last year, the Accounts Receivables growth was 7%. The average annual Accounts Receivables growth rates for Eisai Co Ltd have been 6% over the past three years , 5% over the past five years , and 2% over the past ten years .

Back to Top